Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - citalopram hydrobromide; citalopram -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - doxepin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - selegiline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - nicorandil -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluvoxamine maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

doxepin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - zolpidem tartrate -

United States - English - NLM (National Library of Medicine)

lupin limited - imipramine pamoate (unii: mc34p30298) (imipramine - unii:ogg85sx4e4) - imipramine pamoate 75 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. the use of maois intended to treat psychiatric disorders with imipramine pamoate or within 14 days of stopping treatment with imipramine pamoate is contraindicated because of an increased risk of serotonin syndrome. the use of imipramine pamoate within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration). starting imipramine pamoate in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration). the drug is contraindicated during the acute recovery period after a myocardial infarction. patients with a known hypersensitivity to this compound should not be given the

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - imipramine pamoate (unii: mc34p30298) (imipramine - unii:ogg85sx4e4) - imipramine pamoate 75 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. the use of maois intended to treat psychiatric disorders with imipramine pamoate or within 14 days of stopping treatment with imipramine pamoate is contraindicated because of an increased risk of serotonin syndrome. the use of imipramine pamoate within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration). starting imipramine pamoate in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration). the drug is contraindicated during the acute recovery period after a myocardial infarction. patients with a known hypersensitivity to this compound should not be given the

United States - English - NLM (National Library of Medicine)

stat rx usa llc - imipramine pamoate (unii: mc34p30298) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 75 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine pamoate capsules in patients receiving a monoamine oxidase inhibitor, as long an interval should elapse as the clinical situation will allow, with a minimum of 14 days. initial dosage should be low and increases should be gradual and cautiously prescribed. the drug is contraindicated during the acute recovery period after a myocardial infarction. patients with a known hypersensitivity to this compound should not be given the drug. the possibility of cross-sensitivity to other dibenzazepine compounds shoul